Background: Hypoglycaemia is common in preterm and intrauterine growth retarded (IUGR) newborns. Although preterm and IUGR infants have limited adipose tissue stores, the role of adipose tissue and the associated adipocytokines in glucose physiology is not known. Aim: We report the case of a premature intrauterine growth retarded infant who had poor weight gain for the first 6 weeks of life and then developed severe hypoinsulinaemic hypoketotic hypoglycaemia. Results: There was markedly reduced adiposity with low serum leptin and adiponectin levels. Total energy expenditure and body composition measurements showed that body fat as a percentage of weight averaged 7% at 20 weeks and 28% at 28 weeks. At 20 weeks of age, the patient was equivalent to a deficit of >2 SD scores of body fat, but average fatness by 28 weeks. The hypoglycaemia completely resolved when the patient started gaining weight with an increase in fat mass and a concomitant increase in serum leptin and adiponectin level. Conclusions: Although the precise mechanism of this patient’s severe hypoglycaemia is unclear, further studies are required to understand the role of adipose tissue and adipocytokines in glucose homeostasis in preterm and IUGR infants.

Keywords:
Hypoinsulinaemic hypoglycaemia, Intrauterine growth retardation, Poor weight gain, Reduced adipose tissue
1.
Hawdon JM, Weddell A, Aynsley-Green A, Ward Platt MP: Hormonal and metabolic response to hypoglycaemia in small for gestational age infants. Arch Dis Child 1993;68:269–273.
2.
Collins JE, Leonard JV, Teale D, Marks V, Williams DM, Kennedy CR, Hall MA: Hyperinsulinaemic hypoglycaemia in small for dates babies. Arch Dis Child 1990;65:1118–1120.
3.
Collins JE, Leonard JV: Hyperinsulinism in asphyxiated and small-for-dates infants with hypoglycaemia. Lancet 1984;ii:311–313.
4.
Yu VY, Upadhyay A: Neonatal management of the growth-restricted infant. Semin Fetal Neonatal Med 2004;9:403–409.
5.
Hussain K, Aynsley-Green A: The effect of prematurity and intrauterine growth restriction on glucose metabolism in the newborn. Neoreviews 2004;5:e365–e369.
6.
Uthaya S, Thomas EL, Hamilton G, Dore CJ, Bell J, Modi N: Altered adiposity after extremely preterm birth. Pediatr Res 2005;57:211–215.
7.
Harrington TA, Thomas EL, Frost G, Modi N, Bell JD: Distribution of adipose tissue in the newborn. Pediatr Res 2004;55:437–441.
8.
Havel PJ: Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 2002;13:51–59.
9.
Yang Q, Graham TE, Mody N, Preitner F, Peroni OD, Zabolotny JM, Kotani K, Quadro L, Kahn BB: Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature 2005;436:356–362.
10.
Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR: Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 1983;57:488–495.
11.
Eisenhofer G, Goldstein DS, Stull R, Keiser HR, Sunderland T, Murphy DL, Kopin IJ: Simultaneous liquid-chromatographic determination of 3,4-dihydroxyphenylglycol, catecholamines, and 3,4-dihydroxyphenylalanine in plasma, and their responses to inhibition of monoamine oxidase. Clin Chem 1986;32:2030–2033.
12.
Hussain K, Bodamer OA, Cameron FJ, Camacho-Hubner C, Soos MA, Jones J, Krywawych S, O’Rahilly S, Aynsley-Green A: Hypoketotic hypofattyacidaemic hypoinsulinaemic hypoglycaemia in a child with hemihypertrophy? A new syndrome. Horm Res 2004;61:222–227.
13.
Davies PS, Ewing G, Lucas A: Energy expenditure in early infancy. Br J Nutr 1989;62:621–629.
14.
Fomon SJ, Haschke F, Ziegler EE, Nelson SE: Body composition of reference children from birth to age 10 years. Am J Clin Nutr 1982;35:1169–1175.
15.
Wells JCK, Davies PSW: Estimation of the energy cost of physical activity in infancy. Arch Dis Child 1998;78:131–136.
16.
Finegold DN, Stanley CA, Baker L: Glycemic response to glucagon during fasting hypoglycemia: an aid in the diagnosis of hyperinsulinism. J Pediatr 1980;96:257–259.
17.
Schirra J, Katschinski M, Weidmann C, Schafer T, Wank U, Arnold R, Goke B: Gastric emptying and release of incretin hormones after glucose ingestion in humans. J Clin Invest 1996;97:92–103.
18.
Reichman CA, Davies PS, Wells JCK, Atkin L, Cleghorn G, Shepherd RW: Centile reference standards for total energy expenditure in infants from 1 to 12 months. Eur J Clin Nutr 2003;57:1060–1067.
19.
Butte NF, Hopkinson JM, Wong WW, Smith EO, Ellis KJ: Body composition during the first 2 years of life: an updated reference. Pediatr Res 2000;47:578–585.
20.
Aynsley-Green A, Hussain K, Hall J, Saudubray JM, Nihoul-Fékété C, De Lonlay-Debeney P, Brunelle F, Otonkoski T, Thornton P, Lindley JK: The practical management of hyperinsulinism in infancy. Arch Dis Child Fetal Neonatal Ed 2000;82:F98–F107.
21.
Baxter RC, Daughaday WH: Impaired formation of the ternary insulin-like growth factor-binding protein complex in patients with hypoglycemia due to non-islet cell tumours. J Clin Endocrinol Metab 1991;73:696–702.
22.
Walters EG, Tavare JM, Denton RM, Walters G: Hypoglycaemia due to an insulin-receptor antibody in Hodgkin’s disease. Lancet 1987;i:241–243.
23.
Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Earley AR, Barnett AH, Prins JB, O’Rahilly S: Congenital leptin deficiency is associated with severe early-onset obesity in humans. Nature 1997;387:903–908.
24.
Barzilai N, Wang J, Massilon D, Vuguin P, Hawkins M, Rossetti L: Leptin selectively decreases visceral adiposity and enhances insulin action. J Clin Invest 1997;100:3105–3110.
25.
Shimabukuro M, Koyama K, Chen G, Wang MY, Trieu F, Lee Y, Newgard CB, Unger RH: Direct antidiabetic effect of leptin through triglyceride depletion of tissues. Proc Natl Acad Sci USA 1997;94:4637–4641.
26.
Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT, Bihain BE, Lodish HF: Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA 2001;98:2005–2010.
27.
Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM: Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab 2001;86:3815–3819.
28.
Garg A: Lipodystrophies. Am J Med 2000;108:143–152.
29.
Chan TF, Yuan SS, Chen HS, Guu CF, Wu LC, Yeh YT, Chung YF, Jong SB, Su JH: Correlations between umbilical and maternal serum adiponectin levels and neonatal birth weights. Acta Obstet Gynecol Scand 2004; 83:165–169.
30.
Kotani Y, Yokota I, Kitamura S, Matsuda J, Naito E, Kuroda Y: Plasma adiponectin levels in newborns are higher than those in adults and positively correlated with birth weight. Clin Endocrinol (Oxf) 2004;61:418–423.
31.
Lindsay RS, Walker JD, Havel PJ, Hamilton BA, Calder AA, Johnstone FD: Adiponectin is present in cord blood but is unrelated to birth weight. Diabetes Care 2003;26:2244–2249.
32.
Banerjee RR, Rangwala SM, Shapiro JS, Rich AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, Steppan CM, Ahima RS, Obici S, Rossetti L, Azar MA: Regulation of fasted blood glucose by resistin. Science 2004;303:1195–1198.
33.
Graham TE, Yang Q, Bluher M, Hammarstedt A, Ciaraldi TP, Henry RR, Wason CJ, Oberbach A, Jansson PA, Smith U, Kahn BB: Retinol-binding protein 4 and insulin resistance in lean, obese, and diabetic subjects. N Engl J Med 2006;354:2552–2563.
34.
Barrios V, Argente J, Pozo J, Hervas F, Munoz MT, Sanchez JI, Hernandez M: Insulin-like growth factor I, insulin-like growth factor binding proteins, and growth hormone binding protein in Spanish premature and full-term newborns. Horm Res 1996;46:130–137.
© 2007 S. Karger AG, Basel
2007
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.